The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Abstract
Nonalcoholic steatohepatitis (NASH), the lynchpin between steatosis and cirrhosis in the spectrum of nonalcoholic fatty liver disorders (NAFLD), was barely recognized in 1981. NAFLD is now present in 17% to 33% of Americans, has a worldwide distribution, and parallels the frequency of central adiposity, obesity, insulin resistance, metabolic syndrome and type 2 diabetes. NASH could be present in one third of NAFLD cases. Age, activity of steatohepatitis, and established fibrosis predispose to cirrhosis, which has a 7- to 10-year liver-related mortality of 12% to 25%. Many cases of cryptogenic cirrhosis are likely endstage NASH. While endstage NAFLD currently accounts for 4% to 10% of liver transplants, this may soon rise. Pathogenic concepts for NAFLD/NASH must account for the strong links with overnutrition and underactivity, insulin resistance, and genetic factors. Lipotoxicity, oxidative stress, cytokines, and other proinflammatory mediators may each play a role in transition of steatosis to NASH. The present “gold standard” management of NASH is modest weight reduction, particularly correction of central obesity achieved by combining dietary measures with increased physical activity. Whether achieved by “lifestyle adjustment” or anti-obesity surgery, this improves insulin resistance and reverses steatosis, hepatocellular injury, inflammation, and fibrosis. The same potential for “unwinding” fibrotic NASH is indicated by studies of the peroxisome proliferation activator receptor (PPAR)- γ agonist “glitazones,” but these agents may improve liver disease at the expense of worsening obesity. Future challenges are to approach NAFLD as a preventive public health initiative and to motivate affected persons to adopt a healthier lifestyle. (Hepatology 2006;43:S99-S112.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Cited by
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870
Sasso, M., Beaugrand, M., de Ledinghen, V., Douvin, C., Marcellin, P., Poupon, R., Sandrin, L., & Miette, V. (2010) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2010.07.005 · Cited by 862
Fraquelli, M., Rigamonti, C., Casazza, G., Conte, D., Donato, M. F., Ronchi, G., & Colombo, M. (2007) · Gut · doi:10.1136/gut.2006.111302 · Cited by 854
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.006 · Cited by 778
Schwenzer, N. F., Springer, F., Schraml, C., Stefan, N., Machann, J., & Schick, F. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.023 · Cited by 749
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Wong, V. W.-S., Wong, G. L.-H., Choi, P. C.-L., Chan, A. W.-H., Li, M. K.-P., Chan, H.-Y., Chim, A. M.-L., Yu, J., Sung, J. J.-Y., & Chan, H. L.-Y. (2010) · Gut · doi:10.1136/gut.2009.205088 · Cited by 648
Hypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624
“Among affected patients, up to one-third may also have nonalcoholic steatotic hepatitis.(13,14) Lipotoxicity, oxidative stress, cytokines and proinflammatory mediators contribute to the progression from steatosis to nonalcoholic steatotic hepatitis.”
BackgroundRatziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Bose, M., Lambert, J. D., Ju, J., Reuhl, K. R., Shapses, S. A., & Yang, C. S. (2008) · The Journal of Nutrition · doi:10.1093/jn/138.9.1677 · Cited by 613
Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma
Luedde, T., Beraza, N., Kotsikoris, V., van Loo, G., Nenci, A., De Vos, R., Roskams, T., Trautwein, C., & Pasparakis, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.016 · Cited by 597
A Human Hepatocellular in Vitro Model to Investigate Steatosis
Gómez-Lechón, M. J., Donato, M. T., Martínez-Romero, A., Jiménez, N., Castell, J. V., & O’Connor, J.-E. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.004 · Cited by 576
Paradis, V., Zalinski, S., Chelbi, E., Guedj, N., Degos, F., Vilgrain, V., Bedossa, P., & Belghiti, J. (2009) · Hepatology · doi:10.1002/hep.22734 · Cited by 571
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2300 · Cited by 554
Positive and Negative Regulation of Insulin Signaling by Reactive Oxygen and Nitrogen Species
Bashan, N., Kovsan, J., Kachko, I., Ovadia, H., & Rudich, A. (2009) · Physiological Reviews · doi:10.1152/physrev.00014.2008 · Cited by 542
Welzel, T. M., Graubard, B. I., Zeuzem, S., El-Serag, H. B., Davila, J. A., & McGlynn, K. A. (2011) · Hepatology · doi:10.1002/hep.24397 · Cited by 543
Bohte, A. E., van Werven, J. R., Bipat, S., & Stoker, J. (2011) · European Radiology · doi:10.1007/s00330-010-1905-5 · Cited by 543
Glucocorticoids, metabolism and metabolic diseases
Vegiopoulos, A., & Herzig, S. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.015 · Cited by 535
McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00052 · Cited by 532
Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma
Xu, M. Z., Yao, T., Lee, N. P. Y., Ng, I. O. L., Chan, Y., Zender, L., Lowe, S. W., Poon, R. T. P., & Luk, J. M. (2009) · Cancer · doi:10.1002/cncr.24495 · Cited by 528
Farrell, G. C., Chitturi, S., Lau, G. K., Sollano, J. D., & NAFLD, F. T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05002.x · Cited by 517
Self-citationWelzel, T. M., Graubard, B. I., El–Serag, H. B., Shaib, Y. H., Hsing, A. W., Davila, J. A., & McGlynn, K. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.020 · Cited by 514
Autophagy in the liver: functions in health and disease
Ueno, T., & Komatsu, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.185 · Cited by 500
Epidemiology of non-alcoholic fatty liver disease in China
Fan, J.-G., & Farrell, G. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.010 · Cited by 502
Self-citationPathophysiology of obesity and its associated diseases
Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C. G., & Jiang, T. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.012 · Cited by 499
Rector, R. S., Thyfault, J. P., Uptergrove, G. M., Morris, E. M., Naples, S. P., Borengasser, S. J., Mikus, C. R., Laye, M. J., Laughlin, M. H., Booth, F. W., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.030 · Cited by 488
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15539 · Cited by 486
Pathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.21 · Cited by 484
Pathology of Nonalcoholic Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2007) · American Journal of Clinical Pathology · doi:10.1309/rtpm1py6ygbl2g2r · Cited by 469
NF-κB inhibition delays DNA damage–induced senescence and aging in mice
Tilstra, J. S., Robinson, A. R., Wang, J., Gregg, S. Q., Clauson, C. L., Reay, D. P., Nasto, L. A., St Croix, C. M., Usas, A., Vo, N., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45785 · Cited by 462
Epidemiology and Natural History of NAFLD and NASH
Ong, J. P., & Younossi, Z. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.009 · Cited by 457
Histopathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i42.5286 · Cited by 449
Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome
Roulot, D., Czernichow, S., Le Clésiau, H., Costes, J.-L., Vergnaud, A.-C., & Beaugrand, M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.020 · Cited by 439
Bile Acids as Metabolic Regulators and Nutrient Sensors
Chiang, J. Y. L., & Ferrell, J. M. (2019) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124344 · Cited by 437
Mantena, S. K., King, A. L., Andringa, K. K., Eccleston, H. B., & Bailey, S. M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.12.029 · Cited by 429
Xu, B., Jiang, M., Chu, Y., Wang, W., Chen, D., Li, X., Zhang, Z., Zhang, D., Fan, D., Nie, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.040 · Cited by 426
Radiologic evaluation of nonalcoholic fatty liver disease
Lee, S. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7392 · Cited by 426
Zivkovic, A. M., German, J. B., & Sanyal, A. J. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.2.285 · Cited by 422
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., Shima, T., Kanbara, Y., Saibara, T., Mori, T., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.01.023 · Cited by 420
Luo, X., Li, H., Ma, L., Zhou, J., Guo, X., Woo, S.-L., Pei, Y., Knight, L. R., Deveau, M., Chen, Y., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.010 · Cited by 415
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Sookoian, S., & Pirola, C. J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.012 · Cited by 406
Redox mechanisms in hepatic chronic wound healing and fibrogenesis
Novo, E., & Parola, M. (2008) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-1-5 · Cited by 406
Eslamparast, T., Poustchi, H., Zamani, F., Sharafkhah, M., Malekzadeh, R., & Hekmatdoost, A. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.068890 · Cited by 405
Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link
Siegel, A. B., & Zhu, A. X. (2009) · Cancer · doi:10.1002/cncr.24687 · Cited by 399
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. V., Gan, L., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 398
Self-citationAmarapurkar, D. N., Hashimoto, E., Lesmana, L. A., Sollano, J. D., Chen, P., Goh, K., & NAFLD, F. T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05042.x · Cited by 395
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Anderson, N., & Borlak, J. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.00001 · Cited by 385
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
Prevalence of non-alcoholic fatty liver disease: population based study
Amarapurkar, D., Kamani, P., Patel, N., Gupte, P., Kumar, P., Agal, S., Baijal, R., Lala, S., Chaudhary, D., & Deshpande, A. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31922-2 · Cited by 375
Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances
Lau, J. K. C., Zhang, X., & Yu, J. (2017) · The Journal of Pathology · doi:10.1002/path.4829 · Cited by 373
“The development of steatosis is followed by progression to NASH in one-third of patients with NAFLD [27].”
BackgroundLee, S. S., Park, S. H., Kim, H. J., Kim, S. Y., Kim, M.-Y., Kim, D. Y., Suh, D. J., Kim, K. M., Bae, M. H., Lee, J. Y., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.008 · Cited by 372
Mutlu, E., Keshavarzian, A., Engen, P., Forsyth, C. B., Sikaroodi, M., & Gillevet, P. (2009) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.01022.x · Cited by 370
GI Epidemiology: nonalcoholic fatty liver disease
ANGULO, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03246.x · Cited by 369
Obesity-Associated Liver Disease
Marchesini, G., Moscatiello, S., Di Domizio, S., & Forlani, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1399 · Cited by 359
Fiorucci, S., Mencarelli, A., Palladino, G., & Cipriani, S. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.001 · Cited by 346
The changing epidemiology of liver diseases in the Asia–Pacific region
Wong, M. C. S., Huang, J. L. W., George, J., Huang, J., Leung, C., Eslam, M., Chan, H. L. Y., & Ng, S. C. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0055-0 · Cited by 344
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Kim, D., & Kim, W. R. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.028 · Cited by 341
From NAFLD in clinical practice to answers from guidelines
Nascimbeni, F., Pais, R., Bellentani, S., Day, C. P., Ratziu, V., Loria, P., & Lonardo, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.044 · Cited by 337
Animal models of NASH: Getting both pathology and metabolic context right
Larter, C. Z., & Yeh, M. M. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05543.x · Cited by 337
Self-citationLiedtke, C., Luedde, T., Sauerbruch, T., Scholten, D., Streetz, K., Tacke, F., Tolba, R., Trautwein, C., Trebicka, J., & Weiskirchen, R. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-19 · Cited by 335
Non-alcoholic fatty liver disease and the metabolic syndrome: An update
Rector, R. S., Thyfault, J. P., Wei, Y., & Ibdah, J. A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.185 · Cited by 332
Gäbele, E., Dostert, K., Hofmann, C., Wiest, R., Schölmerich, J., Hellerbrand, C., & Obermeier, F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.035 · Cited by 324
Barchetta, I., Angelico, F., Ben, M. D., Baroni, M. G., Pozzilli, P., Morini, S., & Cavallo, M. G. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-85 · Cited by 323
Rector, R. S., Thyfault, J. P., Morris, R. T., Laye, M. J., Borengasser, S. J., Booth, F. W., & Ibdah, J. A. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00428.2007 · Cited by 321
Chen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y., Shu, F., Gao, Y., Yuan, L., Zhang, Q., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.11.015 · Cited by 319
Yatsuji, S., Hashimoto, E., Tobari, M., Taniai, M., Tokushige, K., & Shiratori, K. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05640.x · Cited by 318
Changes in Glutathione Content in Liver Diseases: An Update
Vairetti, M., Di Pasqua, L. G., Cagna, M., Richelmi, P., Ferrigno, A., & Berardo, C. (2021) · Antioxidants · doi:10.3390/antiox10030364 · Cited by 313
Chitturi, S., Farrell, G. C., Hashimoto, E., Saibara, T., Lau, G. K., Sollano, J. D., & NAFLD, T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05001.x · Cited by 312
Self-citationYokoo, T., Bydder, M., Hamilton, G., Middleton, M. S., Gamst, A. C., Wolfson, T., Hassanein, T., Patton, H. M., Lavine, J. E., Schwimmer, J. B., et al. (2009) · Radiology · doi:10.1148/radiol.2511080666 · Cited by 303
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease
Tang, Y., Bian, Z., Zhao, L., Liu, Y., Liang, S., Wang, Q., Han, X., Peng, Y., Chen, X., Shen, L., et al. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04471.x · Cited by 294
The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases
Fontecha-Barriuso, M., Martin-Sanchez, D., Martinez-Moreno, J., Monsalve, M., Ramos, A., Sanchez-Niño, M., Ruiz-Ortega, M., Ortiz, A., & Sanz, A. (2020) · Biomolecules · doi:10.3390/biom10020347 · Cited by 294
Histopathology of hepatocellular carcinoma
Schlageter, M., Terracciano, L. M., D’Angelo, S., & Sorrentino, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.15955 · Cited by 294
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
Loria, P., Adinolfi, L. E., Bellentani, S., Bugianesi, E., Grieco, A., Fargion, S., Gasbarrini, A., Loguercio, C., Lonardo, A., Marchesini, G., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.021 · Cited by 294
Adams, L. A., Harmsen, S., St. Sauver, J. L., Charatcharoenwitthaya, P., Enders, F. B., Therneau, T., & Angulo, P. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.18 · Cited by 293
Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
Le, M. H., Devaki, P., Ha, N. B., Jun, D. W., Te, H. S., Cheung, R. C., & Nguyen, M. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173499 · Cited by 287
Discovery of farnesoid X receptor and its role in bile acid metabolism
Chiang, J. Y. L., & Ferrell, J. M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111618 · Cited by 288
PPARs, Obesity, and Inflammation
Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287
Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendía, L., & Sahebkar, A. (2017) · Drug Research · doi:10.1055/s-0043-100019 · Cited by 286
Da Silva, H. E., Teterina, A., Comelli, E. M., Taibi, A., Arendt, B. M., Fischer, S. E., Lou, W., & Allard, J. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-19753-9 · Cited by 283
Sasso, M., Miette, V., Sandrin, L., & Beaugrand, M. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.08.001 · Cited by 283
Qureshi, K. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i26.3540 · Cited by 283
Aubert, J., Begriche, K., Knockaert, L., Robin, M. A., & Fromenty, B. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.04.015 · Cited by 282
Bile Acid Metabolism and Signaling
Chiang, J. Y. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00517.x · Cited by 279
Vitamin E Inadequacy in Humans: Causes and Consequences
Traber, M. G. (2014) · Advances in Nutrition · doi:10.3945/an.114.006254 · Cited by 279
FAN, J. G., JIA, J. D., LI, Y. M., WANG, B. Y., LU, L. G., SHI, J. P., CHAN, L. Y., & CHINESE ASSOCIATION FOR THE STUDY OF LIVER DISEASE (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2010.00476.x · Cited by 278
A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism
Xu, Y., Zalzala, M., Xu, J., Li, Y., Yin, L., & Zhang, Y. (2015) · Nature Communications · doi:10.1038/ncomms8466 · Cited by 277
What are the risk factors and settings for non‐alcoholic fatty liver disease in Asia–Pacific?
Fan, J., Saibara, T., Chitturi, S., Kim, B. I., Sung, J. J. Y., Chutaputti, A., & NAFLD, T. A. W. P. F. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04952.x · Cited by 267
Hepatic Microcirculation in Fatty Liver Disease
Farrell, G. C., Teoh, N. C., & Mccuskey, R. S. (2008) · The Anatomical Record · doi:10.1002/ar.20715 · Cited by 266
Self-citation
Metadata
- Authors
- Farrell, G. C., & Larter, C. Z.
- Venue
- Hepatology
- Published
- 2006-02
- Volume
- 43
- Issue
- Supplement 1
- Pages
- S99-S112
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2047257800
- Cited by
- 2,414
- References
- 157
- FWCI
- 86.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.